Cetrorelix
Cetrotide (GnRH antagonist)
Cetrorelix (Cetrotide (GnRH antagonist)) is a hormonal & sexual research compound. GnRH receptor antagonist — immediately suppresses LH/FSH without the initial testosterone flare of GnRH agonists.
Cetrorelix quick facts
| Reported research dose | 0.25mg-3mg |
| Route | Subq |
| Frequency | 1x Daily (0.25mg) or 3mg dose · Varies |
| Half-life | ~62 hrs (0.25mg) |
| Forms | Injectable |
| Evidence level | FDA-approved (IVF) |
Rapid axis shutdown with no flare — used in fertility and hormonal-manipulation research.
How Cetrorelix works
GnRH receptor antagonist — immediately suppresses LH/FSH without the initial testosterone flare of GnRH agonists.
Proposed benefits
Researched for libido, hormonal signaling and reproductive / sexual function.
Can you actually get Cetrorelix?
A fertility-clinic drug used in IVF cycles. Prescribed inside that setting, not bought.
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Cetrorelix
Graded by what exists behind each claim.
✅ Clinically validated
- Approved with randomized data, used in IVF cycles to prevent a premature LH surge from disrupting a stimulated cycle. The evidence base is narrow but solid — it does one job, in one clinical setting, and does it reliably. Nothing has been trialed outside assisted reproduction.
📊 Correlative data
- Very little community use and no published series outside assisted reproduction. That absence is worth stating plainly: unlike most compounds here there is no anecdotal record to weigh, so the clinical tier is the entire human evidence base.
🧪 Theoretical / extrapolated
- A GnRH antagonist — it blocks the receptor directly rather than overstimulating it.
- That distinction is the clinically useful one: an antagonist suppresses immediately with no flare, where an agonist like triptorelin causes a surge before it suppresses. Which behavior you want depends entirely on the goal.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Cetrorelix actually does
Cetrorelix is a decapeptide built to be un-eatable by peptidases, and its sequence is the argument. The label gives it in full: Ac-D-Nal¹-D-Cpa²-D-Pal³-Ser⁴-Tyr⁵-D-Cit⁶-Leu⁷-Arg⁸-Pro⁹-D-Ala¹⁰-NH₂ U.S. Food and Drug Administration 2025. Count the modifications: an acetyl cap on the N-terminus, a C-terminal amide, and five of the ten residues in the D-configuration — positions 1, 2, 3, 6 and 10 — plus four residues that are not proteinogenic amino acids at all (2-naphthylalanine, 4-chlorophenylalanine, 3-pyridylalanine and citrulline). Native GnRH is a decapeptide with a serum half-life of a few minutes. This one is the same length and survives for days, and every one of those substitutions is why.
The pharmacology is the boring kind, which here is the point. The label's own wording: cetrorelix “competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner” U.S. Food and Drug Administration 2025. Straight competitive antagonism at the GnRH receptor on the pituitary gonadotroph. No signal is transduced, so nothing downstream is stimulated at any point.
That is the entire difference from a GnRH agonist, and it is a difference in time course rather than in endpoint. A GnRH agonist — leuprolide, triptorelin — binds the same receptor and activates it. Because the gonadotroph is built to read pulses, continuous activation desensitizes and internalizes the receptor, and suppression follows. But the first thing that happens is a flare: LH and FSH surge, and gonadal steroid output surges with them, for days. An antagonist skips that entirely. Garcia-Velasco 2001 compared ovarian steroid secretion in vivo under a GnRH agonist versus cetrorelix and is the study that documents the two receptor strategies producing different steroid profiles in the same tissue.
How fast, exactly. The label states the onset of LH suppression is approximately one hour with the 3 mg dose and two hours with the 0.25 mg dose U.S. Food and Drug Administration 2025. That is a dose-dependent onset for a receptor-occupancy drug, which is what you would expect: the higher concentration reaches the occupancy threshold sooner. It is also, in practical terms, the fastest deliberate shutdown of the reproductive axis available by any route.
What that means for a male axis, extrapolated and labeled as such. The gonadotroph is the same cell in both sexes and reads the same receptor. Blocking it in a man removes LH support to the Leydig cell and FSH support to the Sertoli cell — so testosterone falls toward castrate concentrations and spermatogenesis loses its drive, with a lag set by the half-life of the existing hormone rather than by the drug. No trial has measured this with cetrorelix in men at these doses, and the direction is not in doubt.
Cell, rodent, human — and where it stops
Step one, healthy human volunteers, and this is the dose-finding backbone. Duijkers 1998 gave 36 healthy female volunteers cetrorelix at 0.25, 0.50 or 1.00 mg subcutaneously — a single dose in one menstrual cycle, then daily dosing from cycle day 3 to 16 in the next. Cmax was reached at 1 hour and both Cmax and AUC rose linearly with dose. FSH, LH, estradiol and progesterone were suppressed with a nadir at 6–12 hours after the dose. On repeated dosing, ovulation was delayed by 5, 10 and 13 days at 0.25, 0.50 and 1.00 mg respectively. That is a clean, dose-ordered, quantitative pharmacodynamic result and it is the reason this drug's dosing is not guesswork.
Step two, the clinical question the drug exists to answer. Olivennes 1998 ran a dose-finding study of a single-dose protocol, 3 mg versus 2 mg, in IVF-embryo transfer. The whole problem being solved is narrow and specific: during controlled ovarian stimulation a premature LH surge triggers ovulation before the eggs can be retrieved, and the cycle is lost. Cetrorelix's job is to hold that surge off for as many days as the stimulation needs.
Step three, the approval, and read the indication literally. Cetrotide is indicated “for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation” U.S. Food and Drug Administration 2025. One sentence, one sex, one procedure. Two regimens are approved: 0.25 mg daily starting on stimulation day 5 or 6 and continuing until hCG, or a single 3 mg dose given when estradiol reaches about 400 pg/mL — usually day 7, range day 5–12 — with 0.25 mg daily resuming 96 hours later if hCG has not been given within 4 days.
The obstacle, and it is unusually total. Every number above was generated in women, most of them mid-stimulation in an IVF cycle, and the endpoint was always the timing of an LH surge over a window of days. There is no trial of cetrorelix in men at these doses for any purpose this site's readers have — not for axis suppression, not for a deliberate reset, not for anything. The receptor is identical and the direction of effect is not in question; what is entirely unmeasured is the magnitude and duration in a male, and there is a specific reason to expect it to differ. The approved regimens are designed to hold a surge for days inside a cycle that is being driven hard by exogenous gonadotropins. A man's axis is not being driven, so the same occupancy is being applied against a far smaller stimulus, and nobody has published what that does or how long it lasts.
Cetrorelix pharmacokinetics — how much of it actually gets in
Route: subcutaneous, and it is one of the few peptides on this site with a measured absolute bioavailability. The label gives 85% U.S. Food and Drug Administration 2025. Volume of distribution 1 L/kg, total clearance 1.28 mL/min per kg. Those are real numbers from a real program and they are not available for most of what this Vault contains.
The half-life is dose-dependent, and this site's card has it attached to the wrong dose. The label's own figures U.S. Food and Drug Administration 2025: after a single 3 mg subcutaneous dose, Cmax 28.5 ng/mL, Tmax 1.5 hours, terminal half-life 62.8 hours. After a single 0.25 mg dose, Cmax 4.97 ng/mL, Tmax 1.0 hour, terminal half-life 5.0 hours. On repeated 0.25 mg dosing, Cmax rises to 6.42 ng/mL and the terminal half-life to 20.6 hours. Duijkers 1998 independently reports a median terminal half-life of 5 to 10 hours after single doses and 20 to 80 hours on multiple dosing. The card on this page reads ‘~62 hrs (0.25 mg)’; 62.8 hours is the 3 mg number, and the 0.25 mg number is roughly twelve times shorter. That is not a trivial correction — it is the difference between a dose that is gone by the next morning and one that is still working three days later.
Why the half-life stretches with dose and with repetition. Cetrorelix forms a subcutaneous depot; absorption from that depot, not elimination, becomes the rate-limiting step at higher amounts. The terminal phase you measure is then the emptying of the depot rather than the clearance of the drug, which is why 3 mg looks twelve times longer-lived than 0.25 mg despite being the same molecule with the same clearance.
What degrades it, and where it goes. The label reports that after subcutaneous administration, cetrorelix plus small amounts of the (1-9), (1-7), (1-6) and (1-4) peptide fragments were found in bile over 24 hours, and that only 7–14% of the total dose was recovered as unchanged cetrorelix and metabolites in urine and bile up to 24 hours U.S. Food and Drug Administration 2025. Two things follow. The degradation is peptidase cleavage from the C-terminal end — the fragments are all N-terminal, which is exactly what an acetyl-capped N-terminus with three D-residues at the front would predict. And the low recovery means most of the dose is still somewhere in the body at 24 hours, which is the depot again.
The consequence for anyone timing anything. Five half-lives of a 3 mg dose is about 13 days; five half-lives of a single 0.25 mg dose is about 25 hours. Those two regimens are not the same drug used at different strengths — they are a short reversible block and a fortnight-long one, and the choice between them is the most consequential decision on this page.
What would have to be true, and how you would know it was not
Four predictions with a marker, a direction and a window. The third corrects something this site's own card gets backwards, and the fourth is the one that cuts against using this at all.
1. LH & FSH should fall within hours, and the nadir has a published time. Duijkers 1998 measured the nadir of FSH, LH and estradiol at 6–12 hours after a subcutaneous dose, and the label puts the onset of LH suppression at 1 hour for 3 mg and 2 hours for 0.25 mg U.S. Food and Drug Administration 2025. So the falsifying draw is not a week later — it is LH & FSH at 8 hours after the injection. If gonadotropins have not moved by then, the material is not cetrorelix or it is not being absorbed.
2. Total Testosterone should follow LH down, one to three days behind it. Leydig-cell output tracks LH with a lag, so draw Total Testosterone at baseline, at 72 hours and at 7 days. This step is extrapolation — the published endocrine data is in women and the downstream steroid measured was estradiol — but the intermediate step, gonadotropin suppression, is measured, and the Leydig cell has no other input.
3. Hematocrit should NOT rise, and this page's inherited interference table says it will. The shared block for this category predicts rising hemoglobin and hematocrit on the grounds that androgens stimulate erythropoiesis. That is true of the stimulating half of this category — hCG, gonadorelin, kisspeptin — and it is exactly backwards for a GnRH antagonist, which lowers androgens. The correct prediction is the opposite: on sustained cetrorelix, hemoglobin and hematocrit should drift down, because androgen-driven erythropoiesis is being withdrawn. Draw a Complete Blood Count (CBC) with Differential at baseline and 8 weeks if the exposure is anything other than brief. A rising hematocrit on cetrorelix would mean the mechanism is not doing what the label says it does.
4. The prediction that cuts against it: everything a hypogonadal state does, it should do. Sustained suppression is chemical castration, and the read-outs are the ones any endocrinology text gives: Estradiol, Sensitive (LC/MS-MS) falling with testosterone; bone turnover rising if the exposure runs months; mood, libido and energy following the steroids down. There is no version of this drug working as designed that does not produce those. Anybody using a GnRH antagonist expecting a ‘reset’ should be clear that the mechanism has no reset in it — it has an off switch, and what happens when the switch is released has never been measured in a man.
What nobody has tested yet
Nobody has measured recovery of the male axis after cetrorelix. The obvious experiment is small and cheap: give a single 3 mg dose to healthy men, draw LH, FSH and total testosterone at 8 hours, 72 hours, 7, 14 and 28 days, and publish the recovery curve. Every input exists — the drug is approved, the assays are routine, the pharmacokinetics are known U.S. Food and Drug Administration 2025 — and the curve does not exist. It is the single most requested piece of information about this compound in the community and there is no answer to give.
Nobody has tested the antagonist against the agonist in men. Garcia-Velasco 2001 put a GnRH agonist and cetrorelix side by side for ovarian steroid secretion in vivo. The equivalent comparison in men — the flare-then-suppress profile of triptorelin against the immediate suppression of cetrorelix, with testosterone sampled through both — would answer whether the flare matters, and it has never been run.
Nobody has established whether a sub-0.25 mg dose does anything useful. The dose-response in Duijkers 1998 runs from 0.25 mg upward and is linear over that range; nothing below 0.25 mg has been characterized. Whether a fractional dose produces partial, graded gonadotropin suppression — which is what anyone attempting to modulate rather than abolish an axis would want — is unknown and would take one dose-ranging study with an 8-hour LH draw.
Nobody has looked at what a depot-forming peptide does at repeated high doses. The 3 mg terminal half-life of 62.8 hours is a single-dose figure U.S. Food and Drug Administration 2025; the approved single-dose protocol is one injection. What happens to the depot, and to the terminal half-life, if 3 mg is repeated weekly for months has no published answer, and the multiple-dose 0.25 mg data — half-life rising from 5.0 to 20.6 hours on repetition — says the answer is not ‘the same’.
Cetrorelix — its own safety story, not its class's
This is an approved drug with a real adverse-reaction table, and the table is short. From the label U.S. Food and Drug Administration 2025: ovarian hyperstimulation syndrome 3.5%, nausea 1.3%, headache 1.1%. Local site reactions — redness, erythema, bruising, itching, swelling — were typically transient and mild. That is the whole list, in women undergoing controlled ovarian stimulation. For a peptide injected daily into a hormonally driven cycle, that is a remarkably clean profile.
The 3.5% OHSS figure needs reading carefully rather than copying. Ovarian hyperstimulation is a complication of the stimulation protocol these women were on, not an action of a GnRH antagonist — the antagonist is there to protect the cycle, and gonadotropins plus hCG are what enlarge the ovary. It is reported under cetrorelix because it happened to patients taking cetrorelix. A man cannot have it. Carrying that number across to a male page as a risk of the drug would be the exact error this site exists to avoid.
What does transfer is the allergic one. The label carries post-marketing reports of hypersensitivity reactions including anaphylactoid responses U.S. Food and Drug Administration 2025. This is a synthetic decapeptide containing three non-natural amino acids, given subcutaneously; hypersensitivity is the failure mode such a molecule has, it is not dose-dependent, and it can occur on a repeat exposure after an uneventful first one. Nothing else on this page is life-threatening and this is.
The real risk of this compound in the use this site's readers have is the mechanism succeeding. Cetrorelix works. A 3 mg dose with a 62.8-hour terminal half-life U.S. Food and Drug Administration 2025 produces roughly a fortnight of receptor blockade at the top of the axis, and the consequence of blocking that receptor in a man is falling testosterone and falling spermatogenic drive. There is no published male recovery curve, so anybody who overshoots has no data telling them how long they will be waiting. The dose difference between the two approved regimens is twelvefold in duration and the community half-life figure — 62 hours attached to the 0.25 mg dose — points the wrong way at exactly the moment it matters.
And a use-context warning that is not pharmacological. The label's dosing is written against estradiol thresholds and ultrasound-monitored follicular growth U.S. Food and Drug Administration 2025; the drug is designed to be given inside a monitored cycle by people watching a specific hormone rise in real time. Used outside that setting there is no feedback signal at all, which is why the 8-hour LH draw in the prediction section is worth more here than on almost any other page in this Vault.
Sources read for this page
- U.S. Food and Drug Administration. CETROTIDE (cetrorelix acetate) for injection, for subcutaneous use - full prescribing information (NDA 021197).. FDA approved labeling, revision 2025
- Duijkers IJ, Klipping C, Willemsen WN, Krone D, Schneider E, Niebch G, Hermann R. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers.. Hum Reprod 1998 · PMID 9806255
- Olivennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Baroux J, Frydman R. The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg.. Hum Reprod 1998 · PMID 9806259
- Garcia-Velasco JA, Isaza V, Vidal C, Landazabal A, Remohi J, Simon C, Pellicer A. Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix).. Hum Reprod 2001 · PMID 11726570
Cetrorelix — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These act on the top of the reproductive axis, and which direction they push depends on how they are given. hCG and gonadorelin stimulate; kisspeptin stimulates upstream of GnRH. Continuous GnRH agonism (triptorelin) paradoxically SUPPRESSES after an initial flare, because sustained signaling desensitizes the receptor. Cetrorelix is a straightforward antagonist and suppresses immediately.
- The predicted harm follows the direction: stimulation raises testosterone and estradiol together, so aromatization-driven effects arrive with it. Suppression produces a hypogonadal state — low libido, fatigue, mood change, and bone loss if prolonged.
- The initial FLARE on a GnRH agonist is the specific thing to know about: hormones rise sharply before they fall, and symptoms can transiently worsen.
What has actually been reported
- hCG is well characterized in fertility medicine — gynecomastia and fluid retention from the estradiol rise are the common complaints.
- GnRH agonist flare is documented and clinically managed in oncology with an antiandrogen during the first weeks.
How to reduce the risk
Same mechanism as the prediction.
- If using hCG alongside an androgen to preserve testicular function, lower and more frequent beats large and infrequent — the estradiol spike tracks the dose size.
- Anything suppressing the axis for more than a few months needs a bone density conversation, not just a hormone panel.
What it does to your bloodwork
A fact about the assay.
- LH and FSH, total and free testosterone, sensitive estradiol (these raise it more than people expect), and a semen analysis if fertility is the reason you are running it.
Don't run this if
- You have a hormone-sensitive cancer, unless this is being directed by an oncologist — in which case it is their protocol, not one to self-manage.
The honest unknown
- Kisspeptin analogs are early in human study. The axis effect is real and well demonstrated acutely; the consequences of repeated long-term use are not established.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Cetrorelix — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Cetrorelix moves on your bloodwork
Expected direction, not a measured one.
- Complete Blood Count (CBC) with Differential — ↑ expected to rise
Hematocrit and hemoglobin rise — androgens stimulate erythropoiesis. This is the most reliably predictable movement of any compound in the Vault.
What to do: This is the number that decides whether you keep going. Baseline and every 3 months. Dehydration on the draw day inflates it, so hydrate normally or you will chase a false reading. - Total Testosterone — ↑ expected to rise
Expected. Trough vs peak matters enormously — the same protocol reads completely differently depending on when you drew.
What to do: Draw at the same point in the cycle every time or the trend is noise. - LH & FSH — ↓ expected to fall
Suppressed by negative feedback. This is the mechanism, not a side effect — and it is why exogenous androgen shuts down your own production.
What to do: Relevant if fertility matters to you. Worth knowing before, not after. - Estradiol, Sensitive (LC/MS-MS) — ↑ expected to rise
Aromatization converts a fraction to estradiol, and it rises with the androgen. Use the sensitive (LC-MS/MS) assay — the standard immunoassay is unreliable in men and produces numbers people then medicate.
What to do: If you are reading estradiol in a man, the assay choice matters more than the result. - SHBG (Sex Hormone-Binding Globulin) — ↓ expected to fall
Falls with androgen exposure, which raises the free fraction — so free testosterone can climb faster than total.
What to do: Read total and SHBG together; total alone understates what changed. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to worsen
HDL falls, sometimes markedly. Oral 17-alpha-alkylated compounds do this far more aggressively than injectable esters.
What to do: Baseline and 12 weeks. ApoB is the better long-term read than LDL-C. - PSA (Total + Free + % Free) — ↑ expected to rise
Androgens can raise PSA modestly. It does not create prostate cancer that wasn't there, but it can unmask it.
What to do: Baseline before starting matters — without it, a later number has nothing to be compared against.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Cetrorelix in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Cetrorelix
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| LH & FSH | A GnRH antagonist suppresses these directly, with no flare |
| Total Testosterone | The downstream consequence |
| Estradiol, Sensitive (LC/MS-MS) | The other downstream hormone |
The Post-Cycle / Recovery & Fertility panel covers these in one order — 9 markers, $184.50 with the discount applied.
Check results you already have → · All 103 markers A–Z
Cetrorelix — frequently asked questions
What is Cetrorelix?
Cetrorelix (Cetrotide (GnRH antagonist)) is a hormonal & sexual research compound. GnRH receptor antagonist — immediately suppresses LH/FSH without the initial testosterone flare of GnRH agonists.
Is the full Cetrorelix protocol on this page?
The reported research dose is on this page, along with how Cetrorelix works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Cetrorelix?
Cetrorelix has an approximate half-life of ~62 hrs (0.25mg), which is part of what determines how often it's dosed.
What's the evidence behind Cetrorelix?
Current evidence level: FDA-approved (IVF). Cetrorelix is offered for research purposes only and is not an approved medicine.
What Cetrorelix is used for
Cetrorelix appears under 1 goal in the goal router.
Related Hormonal & Sexual compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.